The enhanced expression of the human ABC transporter, cMOAT ( MRP2 / ABCC2 ) , is associated with resistance of tumor cells against platinum -containing compounds, such as cisplatin. Therefore, cMOAT represents an interesting candidate factor for modulation of antineoplastic drug resistance. Two different hammerhead ribozymes, which exhibit high catalytic cleavage activities towards specific RNA sequences encoding cMOAT, were designed. Cleavage sites of these ribozymes are the GUC sites in codons 704 and 708 of the open reading frame in the cMOAT -specific mRNA molecule. Hammerhead ribozymes were in vitro synthesized using bacteriophage T7 RNA polymerase and oligonucleotide primers whereby one primer contains a T7 RNA polymerase promoter sequence. cMOAT -encoding substrate RNA molecules were created by a reverse transcription polymerase chain reaction using RNA prepared from the cisplatin -resistant human ovarian carcinoma cell line A2780RCIS overexpressing the cMOAT -encoding transcript. In a cell -free system, both anti -cMOAT ribozymes cleaved their substrate in a highly efficient manner at a physiologic pH and temperature. The cleavage reaction was dependent on time and ribozyme:substrate ratio for determining specific kinetic parameters.
A cquirement of resistance to antineoplastic agents, at concentrations which were once effective for cancer chemotherapy, is a major obstacle in the clinical treatment of human malignancies. The platinum -containing compound, cisplatin [ cis -dichlorodiamin-platinum (II ) ] , is one of the most widely used anticancer agents active in the treatment of various cancers, including testicular, head and neck, esophageal, lung, ovarian, and bladder tumors. Evidence was provided that cisplatin attacks guanine residues in DNA to form several types of adducts with DNA bases. The two major adducts are Pt -d (GpG ) and Ptd (ApG ) intrastrand cross -links, and the remaining include Pt -(dG ) monoadducts, Pt -d( GpNpG ) intrastrand crosslinks, and Pt ( dG ) 2 interstrand cross -links. 1 However, the rapid development of resistance to cisplatin represents an important challenge to oncologists and laboratory investigators alike.
The mechanisms conferring cisplatin resistance, among others, include the enhanced expression of the ABC ( adenosine triphosphate binding cassette ) transporter cMOAT (canalicular multispecific anion transporter ) , 2 also designated MRP2 (multidrug resistance -associated protein 2), 3 or with regard to the suggestions of the HUGO, Human Gene Nomenclature Committee as ABCC2. Physiologically, this ABC transporter mediates the ATP -dependent transport of a broad range of endogenous and xenobiotic compounds across the apical canalicular membrane of the hepatocyte. 4 Mutations in the cMOAT-encoding gene were shown to cause the Dubin -Johnson syndrome, 5 a rare autosomal recessive disorder characterized by chronic conjugated hyperbilirubinemia due to impaired hepatobiliary transport of nonbile salt organic anions.
Methods for modulation of specific gene expression using antisense oligonucleotides have been developed and have been shown to be useful for suppressing activated genes including oncogenes 6 and drug resistance ±associated genes. 7 Hammerhead ribozymes, catalytic RNA molecules exhibiting endoribonuclease activity directed against a specific mRNA target, have advantages over the use of antisense oligonucleotides because of their side -specific cleavage activities and catalytic potentials. They can cleave any triplet of NUX (N = any nucleotide; X =A, C, or U ) if the flanking sequence is changed appropriately. 8 It was reported that ribozymes were effective against drug resistance ±mediating genes, including the P -glycoprotein± encoding mdr1 gene 9, 10 and the LRP (lung resistance protein ) -encoding transcript. 11 However, a ribozyme directed against the cisplatin resistance ±associated ABC transporter cMOAT has not yet been applied. Accordingly, we designed two hammerhead ribozymes directed against the cMOAT-encoding transcript and characterized the kinetic parameters in a cell -free system. The kinetic parameters revealed a high endoribonucleolytic cleavage activity of both anti -cMOAT hammerhead ribozymes.
MATERIALS AND METHODS

Truncated target transcripts
The complete sequence of the cMOAT-encoding mRNA was analyzed concerning putative secondary structures using the DNASIS 3.0 (Hitachi, Yokohama, Japan ) and the mfold 3.0 ( Washington University, St. Louis, MO; E-mail address: http:/ /mfold2.wustl.edu / $mfold /rna / form1.cgi ) software. Sequence regions were estimated to be particularly suitable for ribozyme cleavage, if these regions contained potential ribozyme cleavage sites in nonbase -paired structures, such as hairpin loops. Two different truncated cMOAT-encoding DNA molecules were generated by polymerase chain reaction (PCR ), which appeared to contain such suitable secondary structures and should allow an easy detection of the cleavage products. Total cellular RNA, prepared from the cMOAT-overexpressing, cisplatin-resistant human ovarian carcinoma cell line A2780RCIS ( not yet published ), acted as a template for arbitrarily primed synthesis of cMOATencoding cDNA used in PCR. The unique forward sense primer cMOAT /sub -fw ( nucleotide [nt ] +2014 to nt + 2036 ) was 5
H -linked with a T7 RNA polymerase promoter sequence: 5
H -TAATACGACTCACTATAGCCTGTCGGCTC-TGGGAAATCCTC -3 H ( T7 promoter ± encoding sequence italicized ) . Oligonucleotide primers used for the amplification of cMOAT substrate -1 ±encoding sequences were cMOAT /sub -fw and cMOAT /sub1 -rev ( nt +2194 to nt +2213 ), 5 H -GCACAGGCCTCCAGTACTTG -3 H , yielding an expected product of 200 nt; for amplification of substrate -2 ±encoding sequences were cMOAT /sub -fw and cMOAT /sub2 -rev (nt + 2223 to nt + 2246 ), 5 H -CCTCCAGGCAGCATTTCCAAGTCT-3 H , yielding an expected product of 233 nt. To generate RNA -encoding DNA templates, the reaction mixture contained 100 ng of cDNA prepared from A2780RCIS cells, 0.2 M of each oligonucleotide primer, 0.2 mM of each dNTP, 50 mM KCl, 10 mM Tris ±HCl, pH 8.3, 1.5 mM MgCl 2 , 0.001% gelatin, and 2 units of AmpliTaq Gold ( Perkin Elmer ) in a final volume of 50 L. Cycling conditions were 12 minutes at 948C followed by 36 cycles consisting of 60 seconds at 948C, 90 seconds at 628C, and 90 seconds at 728C. The last cycle contained a 5 -minute extension step at 728C. Subsequently, the PCR products were purified with Sephadex G -50 columns. The two different cMOATspecific RNA fragments (substrates -1 and -2 ) were obtained by performing an in vitro transcription as described previously. 12 In each case, the sequences and nt positions were derived from human cMOAT cDNA sequence (accession no. X96395 ). 13 Nucleotide position +1 is assigned to the A residue of the ATG translation start codon.
Construction and synthesis of hammerhead ribozymes
According to the secondary structure analysis used for cMOAT substrate selection, the potential hammerhead ribozyme cleavage sites were determined at nt 99 and nt 110 of both substrate. These target sequences are not blocked by any base pairing. Additionally, the different sizes of the cleavage products of the truncated RNA transcripts should allow an easy identification of each fragment. Hammerhead ribozymes were named RzM1 and RzM2 and are shown in Figure 1 . The cleavage reactions with RzM1 should yield a 99 -nt 5
H -product and a 101-nt 3 H -product using substrate -1, and a 99 -nt 5
H -product and a 134 -nt 3 H -product using substrate -2. In contrast, the endoribonucleolytic digestion with RzM2 should yield a 110-nt 5
H -product and a 90 -nt 3 Hproduct using substrate -1, and a 110 -nt 5
H -product and a 123 -nt 3
H -product using substrate -2. For each hammerhead ribozyme, an encoding sense ssDNA 5
H -linked with a T7 RNA polymerase promoter sequence, as well as the homologous antisense ssDNA, was synthesized on an oligonucleotide synthesizer. Sense sequence for RzM1 is 5
H -TAATACGACTCACTATAGTGCTGTGGCTGATGAG-TCCGTGAGGACGAAACATAGGC -3 H and for RzM2 5
H , whereby T7 promoter ±encoding sequences are underlined, respectively. Using these template molecules, the hammerhead ribozymes were obtained by in vitro transcription as described previously. 12 
Cleavage of substrate RNAs
The ability of the both anti -cMOAT hammerhead ribozymes to cleave their target RNA was assayed as described earlier 12 with some modifications. In brief, cleavage reactions were carried out in a final volume of 10 L containing 200 nM hammerhead ribozyme, 200 nM of the target molecule, 40 mM Tris ±HCl, pH 7.5, and 12 mM MgCl 2 at 378C. Samples were removed after various time intervals and quenched by MATERNA, HOLM, DIETEL, ET AL: CMOAT RIBOZYME adding an equal volume of 8 M urea, 8.7% glycerin, 0.02% xylene cyanole, 0.02% bromephenole blue, 0.02% orange G. Each sample was size -fractionated on an 8% polyacrylamide gel containing 7 M urea. Substrates and cleavage products were identified by autoradiography, scanned using the BioRad molecular analyst software package (BioRad, Hercules, CA ), and counted to determine the extent of cleavage. This way, both anti -cMOAT hammerhead ribozymes, RzM1 and RzM2, were estimated to have a high catalytic cleavage activity and were characterized in detail.
Turnover kinetics
Determinations of the values for the initial velocities ( v ini ) and the reaction parameters k cat /k m of the hammerhead ribozymes were performed as described earlier 12 with some modifications. Additionally, the values for the observed cleavage constants k obs were determined. The value of the initial velocity v ini of each cleavage reaction was estimated by measuring the amount of 32 P -labeled substrate and formed cleavage products appearing as time -dependent using 40 nM substrate and 200 nM hammerhead ribozyme. The reaction was started by adding substrate RNA to the reaction mix containing the ribozyme RNA, 40 mM Tris ± HCl, pH 7.5, and 12 mM MgCl 2 at 378C. All experiments were performed at least in triplicate. Substrate:product ratios were estimated following polyacrylamide gel electrophoresis of the reaction mixtures and autoradiography by densitometric measurement using the BioRad molecular analyst software. The values for the initial velocities were calculated from the ascent of the graph in the product ± time diagrams. The linear range of the graphs was assessed by selection of the highest correlation coefficients obtained by the calculation of different linear regression curves using various breakpoints.
For better comparability with kinetic values from the literature determined by different methods, the reaction parameter k cat /k m was calculated using two different commonly used mathematical approaches. (i) The value of k cat /k m was assessed following the equation given by Heidenreich and Eckstein:
where the percentage of uncleaved substrate (S u ) per reaction time ( t) was plotted against the ribozyme concentration ( [ribozyme ] ) . P t is the amount of cleavage products at time (t) . This calculation is based on the accepted supposition that the cleavage of the first 30% of the substrate follows a linear curve and, upon that, the whole amount of given substrate is cleavable. The linear range of the graphs was assessed as described above. Under these circumstances, the k cat / k m value corresponds to the ascent of the linear beginning of the graph. (ii ) The value for k cat /k m was determined by the equation of Hendry et al: 15 P t P I À P e À k cat km tribozyme P t and t are the same as above, P I is the amount of cleavage products at that point of time t =I when the reaction rate was constant, and P Á is the difference between the percentage of cleavage products at t =I and t =0. This calculation is based on the supposition that the cleavage of the first 30% of the substrate follows a linear curve as well, but, in contrast to the upper calculation, regards only that amount of substrate cleavable, which is actually cleaved after a considerable amount of time (here 5 hours; described as t =I ). For these k cat / k m values corresponding to the ascent of the linear beginning of the graphs, it is obvious that the results gained by these two procedures must differ. The linear range of the curve was determined as described above. Experiments were performed for 15 minutes using 40 nM substrate and increasing concentration of hammerhead ribozymes (0 ±400 nM ). The reaction was started by adding the substrate RNA to the reaction mix containing a ribozyme, 40 mM Tris ± HCl, pH 7.5, and 12 mM MgCl 2 at 378C. All experiments were performed at least in triplicate and analyzed as described above.
According to the comparability with alternative published kinetic values, the observed cleavage rates k obs were determined by two methods. ( i) The k obs value was calculated according to Heidenreich et al: 16 k obs À ln S u t whereby the reaction constant k obs equals the negative natural logarithm of the uncleaved substrate ( S u ) divided by the reaction time t. This equation does not take in consideration how much substrate is effectively cleaved.
( ii) The value of k obs was assessed by the improved method of Hendry et al:
15
P t P I À e Àk obs t P where P t is the amount of formed product at time t, P I is the amount of product at t= I, and P is the difference between the percentage of product at t =I and t= 0. This approach regards that the substrate is not cleaved completely in the ribozyme -catalyzed reaction.
RESULTS
The 5
H -linked T7 promoter carrying oligonucleotide primers used for generation of truncated cMOAT-specific RNA substrates was successfully applied for PCR -based DNA template synthesis. These truncated cMOAT-encoding DNA templates were suitable for direct in vitro transcription without any cloning procedure. The same was true for 5 Hlinked T7 promoter sequence containing synthetic DNA molecules, which encoded the two anti -cMOAT hammerhead ribozymes.
The two anti -cMOAT hammerhead ribozymes, RzM1 and RzM2, with symmetric 8 -nt 5
H -antisense and 8 -nt 3 Hantisense flanks were designed according to the method of Haseloff and Gerlach. 17 Both catalytic RNA molecules were tested in a cell -free assay for their ability to cleave in vitro transcribed truncated fragments of the cMOAT-encoding mRNA. The substrate fragment size ranged from 200 to 233 nt. Anti-cMOAT hammerhead ribozymes, RzM1 and RzM2, targeting the GUC motifs 704 and 708, respectively, of the MATERNA, HOLM, DIETEL, ET AL: CMOAT RIBOZYME
cMOAT-encoding open reading frame were very efficiently in cleaving their RNA substrates at physiologic pH and temperature at equimolar concentrations of hammerhead ribozyme and substrate RNA in the cleavage reaction ( Fig  2 ) . For better separation and visualization of the endoribonucleolytic cleavage products after electrophoresis, the kinetic characterization of RzM1 was performed using substrate -2 (Fig 2 demonstrates the excellent possibility to distinguish both products). In contrast, for the characterization of hammerhead ribozyme RzM2, substrate -1 was applied in the experimental procedures. The capacity of both anti -cMOAT hammerhead ribozymes, RzM1 and RzM2, to cleave the target molecules was determined on time ( Fig 3A and B ) and substrate:ribozyme ratio ( Fig 4A and B ) . The amounts of endoribonucleolytic cleavage products were assessed when the turnover rate became constant. For both hammerhead ribozymes, these values (P I ) were typically in the region of 0.8, i.e., $80% of the substrate molecules was cleaved at the end of the reaction. The initial velocities ( v ini ) of the ribozymecatalyzed reactions were calculated as follows: (i ) for ribozyme RzM1, v ini =0.127 0.006 fmol s À 1 (Fig 5A ) and ( ii ) for ribozyme RzM2, v ini = 0.086 0.005 fmol s À 1 ( Fig  5B ) . The values of the reaction parameter k cat /k m were calculated for ribozyme RzM1 as k cat /k m = 9307 312 M À 1 s À 1 (Fig 6A ) according to the equation of Hendry et al 15 and as k cat /k m = 7719 284 M À 1 s À 1 ( Fig 7A ) using the equation given by Heidenreich and Eckstein.
14 The hammerhead ribozyme ± specific values of the reaction rate k obs were determined for ribozyme RzM1 as k obs =8.73Â10 0.33Â10 À 4 s À 1 ( Fig 8A ) using the method of Hendry et al 15 and as k obs = 7.66Â10 À 4 0.29Â10 À 4 s À 1 ( Fig 9A ) according to Heidenreich et al. 16 Assessment of the k cat /k m values for anti -cMOAT ribozyme RzM2 revealed a k cat / k m = 4478 105 M À 1 s À 1 ( Fig 6B ) using the method of Hendry et al, 15 and a k cat /k m = 3671 78 M À 1 s À 1 (Fig 7B ) applying the calculation proposed by Heidenreich and Eckstein.
14 The calculation of the values of the cleavage constant k obs for RzM2 resulted in k obs = 5.79Â10 À 4 0.27Â10 À 4 s À 1 (Fig 8B ) according to the method of Hendry et al 15 and in k obs =4.81Â10
( Fig 9B ) using the equation given by Heidenreich et al. 16 The values of the kinetic parameters of both anti -cMOAT hammerhead ribozymes are presented in comparison with that of other published ribozymes in Table 1 .
DISCUSSION
Two hammerhead ribozymes, RzM1 and RzM2, were constructed to cleave the cisplatin resistance ± associated cMOAT-encoding mRNA transcripts, and the efficiency of cleavage by these ribozymes was examined in a cell -free system. Although hammerhead ribozymes have been applied successfully to cleave the mRNA transcripts of drug resistance ± mediating factors, such as the ABC transporter P -glycoprotein, 9,10 dihydrofolate reductase, 18 or the vault component LRP, 11 no hammerhead ribozymes have been designed to inactivate RNA molecules encoding the cisplatin resistance ± mediating ABC transporter, cMOAT. Therefore, the two anti -cMOAT ribozymes, RzM1 and RzM2, appear as excellent new candidate molecules for modulating cytostatic drug resistance, both as laboratory tools for the elucidation of the relationship between mRNA expression MATERNA, HOLM, DIETEL, ET AL: CMOAT RIBOZYME and a drug -resistant phenotype as well as potential molecules with therapeutic intent. Difficulties in the successful design and application of hammerhead ribozymes can arise because various potential ribozyme cleavage sites in a particular mRNA molecule may not be accessible for base pairing and because cleavable sites often are not foreseeable. 19 Thus, practicable target sites of hammerhead ribozymes often are determined by trial and error. Basing on own experience, 10,12,20 ± 23 the anti-cMOAT ribozymes, RzM1 and RzM2, were designed after computer-based secondary structure analyses of the target mRNA molecules. The decisive criterion for ribozyme design was the fact that they interact with the predicted cleavage sites in putative nonbase -pairing containing RNA structures. Here it could be demonstrated that this strategy rapidly reveals catalytic active molecules.
A further possible problem in ribozyme design is the phenomenon that ribozymes which are found to be catalytically active to cleave short RNA substrates often show poor potency when applied to long RNA substrates. 14, 19 To circumvent this difficulties, the ribozymes were characterized using long truncated RNA substrate molecules ( 200 ±233 nt ). Large RNA molecules can form complex secondary and tertiary structures that can interfere with ribozyme recognition and cleavage sites. Very likely, the rate -limiting step is the bimolecular association of the hammerhead ribozyme with the target sequence. Additionally, tertiary interactions can slow down product release and interfere with turnover. For these reasons, only a few hammerhead ribozymes, which show a high catalytic cleavage activity with long RNA substrate molecules, were designed. 12, 20, 23, 24 The catalytic parameters of both anticMOAT hammerhead ribozymes, RzM1 and RzM2, show . Figure 8 . Experimental determination of the observed reaction constants k obs of the hammerhead ribozymes, RzM1 and RzM2, according to Hendry et al. 15 The values of k obs correspond to the ascent of the apparent linear beginning of the curves ( small inserted figures ) . All experiments were performed at least in triplicate. A: Reaction curve obtained by using RzM1 and substrate -2. The value of k obs was calculated to be k obs = 8.73Â10 values that are comparable with some of these ribozymes ( Table 1 ) indicating that the target sites are very accessible for both anti -cMOAT ribozymes and that both ribozymes exhibit a high catalytic cleavage activity. However, on the basis of the more advantageous kinetic values of v ini and k cat /k m calculated for the anti-cMOAT hammerhead ribozyme RzM1, this catalytic molecule appears to be the better suitable candidate for a potential application. The application of hammerhead ribozymes has been proposed to be a tool in analyzing gene expressions, to modulate the malignancy of a tumor, or to reverse the drugresistant phenotype of cancer cells. Our experiments demonstrate that both anti -cMOAT hammerhead ribozymes may provide potential help in cancer research and may serve as potential modulators of cisplatin resistance applying gene therapeutic strategies. However, the reported data were obtained in a cell -free system, and the relevance in tumor cisplatin -resistant tumor cells remains to be demonstrated. We are currently making efforts to demonstrate these effects in a cellular model. Figure 9 . Determination of the cleavage constant k obs of the anticMOAT ribozymes, RzM1 and RzM2, according to Heidenreich et al. 16 The values of k obs correspond to the ascent of the apparent linear beginning of the curves ( small inserted figures ) . All experiments were performed at least in triplicate. A: Reaction curve obtained by using RzM1 and substrate -2. The value of k obs was calculated to be k obs = 7.66Â10 À 4 0.29Â10 À 4 s À 1 . B: Curve obtained by using RzM2 and substrate -1. The value of k obs was determined to be k obs = 4.81Â10 À 4 0.23Â10 À 4 s À 1 . 
